GMS | Deutscher Rheumatologiekongress 2023 | Tolerability and safety of recombinant zoster vaccine in patients with inflammatory rheumatic musculoskeletal diseases – a prospective longitudinal study over 6 months

Figure 1: Cumulative number of patients with at least one adverse event

gms | German Medical Science